Ropivacaine

Generic Name: Ropivacaine

Brand Names: Naropin

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₆N_₂O

CAS Number: 84057-95-4

Unique Ingredient Identifier: 7IO5LYA57N

Background: Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.

Indication: Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.

Associated Conditions: Acute Pain, Postoperative pain

Associated Therapies: Surgical anesthesia therapy

Clinical Trials

A Study to Compare Laparoscopic to Echographic Assisted Transversus Abdominis Plane Block in Laparoscopic Colectomy

Not Applicable

Completed

Conditions: Laparoscopic Colectomy
Pain, Postoperative

Interventions: Procedure: laparoscopic-assisted Transversus Abdominis Plane (TAP) block
Procedure: ultrasound-assisted Transversus Abdominis Plane (TAP) block
Drug: Ropivacaine

First Posted Date: 2020-10-05

Last Posted Date: 2022-07-14

Lead Sponsor: Davide La Regina

Target Recruit Count: 116

Registration Number: NCT04575233

Locations: 🇨🇭
Ospedale Regionale Bellinzona e Valli, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
🇨🇭
Ospedale Regionale di Lugano, Civico e Italiano - Ente Ospedaliero Cantonale, Lugano, Switzerland

Ropivacaine Plasma Concentration With or Without Epinephrine for Posterior Quadratus Lumborum Block

Not Applicable

Completed

Conditions: Anesthesia, Local
Local Anesthetic Systemic Toxicity

Interventions: Drug: Epinephrine / Ropivacaine
Drug: Ropivacaine

First Posted Date: 2020-09-24

Last Posted Date: 2020-10-08

Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Target Recruit Count: 52

Registration Number: NCT04562103

Locations: 🇮🇹
IRCCS Policlinico Agostino Gemelli, Rome, Italy

A Trial of HR18034 in Inguinal Hernia Repair

Phase 1

Conditions: Inguinal Hernia Repair

Interventions: Drug: HR18034
Drug: Naropin

First Posted Date: 2020-09-16

Last Posted Date: 2020-09-16

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 64

Registration Number: NCT04551924

Locations: 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China

Administration of Ropivacaine by Bi-laterosternal Multiperforated Catheters Placed Before a Sternotomy for Cardiac Surgery

Phase 2

Completed

Conditions: Scheduled Cardiac Surgery
Age Under 85 Years

Interventions: Drug: Ropivacaine

First Posted Date: 2020-08-03

Last Posted Date: 2022-12-05

Lead Sponsor: University Hospital, Clermont-Ferrand

Target Recruit Count: 32

Registration Number: NCT04495504

Locations: 🇫🇷
CHU Clermont-Ferrand - Service de Chirurgie Cardio-Vasculaire, Clermont-Ferrand, Puy De Dôme, France

WALANT Technique (Wide Awake Local Anesthesia No Tourniquet) for Carpal Tunnel Release.

Not Applicable

Completed

Conditions: Carpal Tunnel Release

Interventions: Procedure: TRONC
Procedure: Tourniquet
Procedure: WALANT
Drug: Ropivacaine
Drug: Lidocaine + Epinephrine

First Posted Date: 2020-07-31

Last Posted Date: 2021-07-23

Lead Sponsor: CMC Ambroise Paré

Target Recruit Count: 60

Registration Number: NCT04494100

Locations: 🇫🇷
Clinique Jouvenet, Paris, Ile-de-France, France
🇫🇷
Clinique Rémusat, Paris, Ile-de-France, France

Quadratus Lumborum vs Erector Spinae Supplementary Blocks With Lumbar Plexus Blocks for Hip PAO

Phase 4

Active, not recruiting

Conditions: Hip Dysplasia
Regional Anesthesia
Pain, Postoperative

Interventions: Procedure: Quadratus lumborum block with ropivacaine 0.2%
Procedure: Erector spinae block with ropivacaine 0.2%
Drug: Ropivacaine

First Posted Date: 2020-07-22

Last Posted Date: 2024-01-31

Lead Sponsor: Boston Children's Hospital

Target Recruit Count: 156

Registration Number: NCT04481451

Locations: 🇺🇸
Boston Children"S Hospital, Boston, Massachusetts, United States

Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery

Phase 4

Completed

Conditions: Analgesia

Interventions: Drug: Dexmedetomidine
Drug: Ropivacaine
Drug: Dexamethasone

First Posted Date: 2020-05-19

Last Posted Date: 2022-01-04

Lead Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche

Target Recruit Count: 122

Registration Number: NCT04394481

Locations: 🇫🇷
Hôpital privé jean Mermoz, Lyon, France

Effects of Pre-emptive Scalp Infiltration With Low-dose Ketorolac and Ropivacaine for Postoperative Pain

Phase 4

Conditions: Pain
Supratentorial Brain Tumor

Interventions: Drug: Ropivacaine
Drug: Ketorolac
Drug: Epinephrine

First Posted Date: 2020-05-08

Last Posted Date: 2020-09-09

Lead Sponsor: Beijing Tiantan Hospital

Target Recruit Count: 40

Registration Number: NCT04380298

A Randomized Control Trial Comparing Analgesic Benefits of Ultrasound-guided Single vs Continuous Quadratus Lumborum Blocks (QLB)vs Intrathecal Morphine(ITM) for Post Cesarean Section Pain

Phase 4

Terminated

Conditions: Pain, Postoperative

Interventions: Drug: Intrathecal morphine sulfate (ITM)
Drug: Bupivacaine hydrochloride
Drug: ropivacaine hydrochloride

First Posted Date: 2020-04-29

Last Posted Date: 2022-05-16

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 3

Registration Number: NCT04368364

Locations: 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
🇺🇸
Memorial Hermann Hospital TMC, Houston, Texas, United States

MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery

Phase 3

Completed

Conditions: Malignant Neoplasm of Breast

Interventions: Drug: Saline
Drug: Ropivacaine

First Posted Date: 2020-03-30

Last Posted Date: 2024-01-29

Lead Sponsor: Institut Curie

Target Recruit Count: 182

Registration Number: NCT04327063

Locations: 🇫🇷
Institut Curie, Paris, France
🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷
Hopital Tenon, Paris, France

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy